Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YY-162 in Children With ADHD
NCT01201187Phase 3Completed
- Sponsor
- Yuyu Pharma
- Start
- Mar 2010
- Primary completion
- Apr 2010
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ginkgo biloba extract, YY-162 in attention deficit hyperactivity disorder (ADHD), sponsored by Yuyu Pharma. Started Mar 2010; status: completed.
02
Drugs
ginkgo biloba extractYY-162
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01201187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01201187.